Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 172 MF tasquinimod study in myelofibrosis
NL-OMON59215Phase 2Suspended
- Sponsor
- HOVON
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tasquinimod in myelofibrosis (MF) (2 arms), sponsored by HOVON. Primary endpoints: Dose-limiting toxicity, Recommended phase 2 dose and 1 more. Started Feb 2025; status: suspended.
02
Drugs
tasquinimod
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NL-OMON59215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59215.